TABLE 4.
Summary of results from longitudinal studies with population-based samples regarding the relationship between DHEAS and health or survival
| All-cause Mortality | Functional Limitations | Depressive Symptoms | Cognitive Impairment | Poor Self-Assessed Health Status | |||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Study Reference | Dataset/Cohort, Length of Follow-up | M | F | M | F | M | F | M | F | M | F |
| Current Study | SEBAS (Taiwan), 3 years | ↓ | N.S. | ↓ | N.S. | ⋃ | N.S. | ↓ | N.S. | ||
| Birkenhager-Gillesse et al., 1994 | Leiden (Netherlands), 1 year | N.S. | N.S. | ||||||||
| Glei and Goldman, 2006 | SEBAS (Taiwan), 3 years | N.S. | N.S. | ||||||||
| Tilvis et al., 1999 | Helsinki Aging Study (Finland), 5 years | N.S. | N.S. | ||||||||
| Barrett-Connor et al., 1986 | Rancho Bernardo, CA (US), 12 years | ↓ | |||||||||
| Berr et al., 1996 a | PAQUID (France), 4 years | ↓ | N.S. | N.S. | N.S. | ||||||
| Mazat et al., 2001 a | PAQUID (France), 9 years | ↓ | N.S. | N.S. | N.S. | ↓ | N.S. | N.S. | N.S. | ||
| Trivedi and Khaw, 2001 | Cambridge General Practice Health Study (England), 5–9 years | ↓ | N.S. | ||||||||
| Cappola et al., 2006 | WHAS (US), 5 years | ⋃ | |||||||||
| Barrett-Connor and Goodman-Gruen, 1995 | Rancho Bernardo, CA (US), 19 years | ↑ | ↑ | ||||||||
| Yaffe et al., 1998 | Study of Osteoporotic Fractures (US), 2 years | ↓ | |||||||||
| Barrett-Connor and Edelstein, 1994b | Rancho Bernardo, CA (US), 16 years | N.S. | N.S. | ||||||||
↓ Higher levels of DHEAS associated with lower risk (p<0.05); ↑ Higher levels of DHEAS associated with greater risk (p<0.05); ⋃ Both low and high levels of DHEAS are associated with greater risk (p<0.05); N.S. No significant relationship.
a
The original cohort (n=2792) comprises a population-based sample, but analyses are based on a sub-sample (n=622) of volunteers who agreed to blood sampling.
b
Study examined five measures of cognitive function; DHEAS was significant for only one of these outcomes and only for females.